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KAE609 represents a new class of potent, fast-acting, schizonticidal antimalarials. This study investigated the safety and pharma-
cokinetics of KAE609 in combination with the long-acting antimalarial piperaquine (PPQ) in healthy volunteers. A two-way
pharmacokinetic interaction was hypothesized for KAE609 and PPQ, as both drugs are CYP3A4 substrates and inhibitors. The
potential for both agents to affect the QT interval was also assessed. This was an open-label, parallel-group, single-dose study
with healthy volunteers. Subjects were randomized to four parallel dosing arms with five cohorts (2:2:2:2:1), receiving 75 mg
KAE609 plus 320 mg PPQ, 25 mg KAE609 plus 1,280 mg PPQ, 25 mg KAE609 alone, 320 mg PPQ alone, or 1,280 mg PPQ alone.
Triplicate electrocardiograms were performed over the first 24 h after dosing, with single electrocardiograms at other time
points. Routine safety (up to 89 days) and pharmacokinetic (up to 61 days) assessments were performed. Of the 110 subjects re-
cruited, 99 completed the study. Coadministration of PPQ had no overall effect on exposure to KAE609, although 1,280 mg PPQ
decreased the KAE609maximum concentration (Cmax) by 17%. The group that received 25 mg KAE609 plus 1,280 mg PPQ
showed a 32% increase in the PPQ area under the concentration-time curve from 0 to infinity (AUCinf), while the group that re-
ceived 75 mg KAE609 plus 320 mg PPQ showed a 14% reduction. Mean changes from baseline in the QT interval corrected by
Fridericia’s method (QTcF) and the QT interval corrected by Bazett’s method (QTcB) with PPQwere consistent with its known
effects. PPQ but not KAE609 exposure correlated with corrected QT interval (QTc) increases, and KAE609 did not affect the PPQ
exposure-QTc relationship. The QTcF effect for PPQ (least-squares estimate of the difference in meanmaximal changes from
baseline of 7.47 ms [90% confidence interval, 3.55 to 11.4 ms]) was consistent with the criteria for a positive thorough QT study.
No subject had QTcF or QTcB values of>500 ms. Both drugs given alone or in combination were well tolerated, with no deaths,
serious adverse events (AEs), or severe AEs reported. Most AEs were mild; upper respiratory tract infections, headache, diarrhea,
and oropharyngeal pain were most common. PPQ and KAE609 coadministration had no relevant effect on exposure to either
agent, and KAE609 did not affect or potentiate the known effects of PPQ on cardiac conduction.
Malaria-related fatalities have declined substantially in thepast 15 years. However, the World Health Organization
(WHO) still reported an estimated 207 million malaria cases in
2012, leading to 627,000 deaths (1). Most malaria-related deaths
are of children under the age of 5 years, who lack the partial im-
munity that often protects adults living in areas in which the dis-
ease is endemic from severe disease (1). About a decade ago,WHO
began recommending artemisinin-based combination therapies
as the first-line treatment for uncomplicated Plasmodium falcipa-
rum infections (2). Alarmingly, resistance to artemisinin has now
become geographically widespread across Southeast Asia (3). It is
feared that this resistance will become more prevalent and spread
globally, as has occurred with all prior classes of antimalarials.
Novel, non-artemisinin-based antimalarial drugs are critically
important in this changing disease landscape.
KAE609 (cipargamin) is a spiroindolone with potent activity
against blood-stage malaria parasites (4, 5). The compound was
safe and tolerable and had approximately linear pharmacokinetics
(PK) in healthy volunteers at single doses up to 300 mg and mul-
tiple doses up to 150 mg once daily for 3 days (6). A phase 2 study
of KAE609 in 21 adults with uncomplicated Plasmodium vivax
(n  10) or P. falciparum (n  11) malaria was conducted in
Bangkok and on the Thai-Myanmar border (7). Once-daily dos-
ing of KAE609 at 30 mg for 3 days resulted in median parasite
clearance (CL) times of approximately 12 h for both P. vivax and
P. falciparum, including in patients with artemisinin resistance.
Furthermore, the median parasite clearance half-life (t1/2) values
were 0.95 h for patients with P. vivax and 0.90 h for those with P.
falciparum. These preliminary data suggest a parasite clearance
rate comparable to or faster than that of artemisinin. Treatment
with KAE609 was well tolerated by the patients; nausea was the
most common adverse event (AE) (7).
Treatment of malaria with monotherapy is strongly discour-
aged, due to the risk of resistance. Therefore, for clinical use, an-
timalarial compounds are combined with at least one other drug,
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representing a different mode of action. One potential combina-
tion partner for KAE609 is piperaquine (PPQ). PPQ is an ap-
proved antimalarial that is currently available in fixed-dose com-
bination with dihydroartemisinin under the label Eurartesim
(Sigma-Tau and Medicines for Malaria Venture). Eurartesim is
well tolerated (8), although PPQ is known to have effects on car-
diac conduction, most notably in terms of exposure-related cor-
rected QT interval (QTc) prolongation, with no plateau of effect
described in the range examined and a duration of at least 24 h (9,
10). For KAE609, no significant changes in electrocardiographic
(ECG) parameters have been observed in clinical studies con-
ducted to date (7); however, preclinical studies (in vitro and in
animals) have suggested a potential risk for QTc prolongation.
KAE609 is metabolized by CYP3A but does not appear to in-
duce it, and it has the potential to inhibit CYP3A, based on in vitro
data (unpublishedNovartis data). PPQ ismetabolized byCYP3A4
and can also inhibit the enzyme (9); hence, a two-way interaction
during drug exposure was hypothesized. The primary objective of
this study was to evaluate the safety and drug-drug interaction
potential of KAE609 and PPQ. Triplicate ECG evaluations were
conducted to evaluate possible QT interval changes in the pres-
ence of both drugs.
MATERIALS AND METHODS
Subjects. Eligible subjects were healthymale and female subjects, 18 to 45
years of age and weighing at least 50 kg. Vital signs measured at screening
and baseline had to be within normal ranges (oral body temperature, 35.0
to 37.5°C; systolic blood pressure, 90 to 140mmHg; diastolic blood pres-
sure, 50 to 90 mm Hg; pulse rate, 40 to 90 beats/min). Women of child-
bearing potential were excluded from this study. Other exclusion criteria
included a history or the presence of clinically significant ECG abnormal-
ities or arrhythmias (PR interval of200ms, QRS interval of120ms, or
QT interval corrected by Fridericia’s method [QTcF] of430 ms [male]
or 440 ms [female]) and a family history or the presence of long QT
syndrome. Subjects were excluded if they had hypersensitivity to any of
the study drugs or similar chemical classes, food allergies, or a history of
malignancy, autonomic dysfunction, bronchospastic disease, conditions
that might alter drug absorption, distribution, metabolism, or excretion,
or pancreatic, liver, or renal dysfunction. Subjects with hepatitis B virus
(HBV), hepatitis C virus (HCV), HIV, or other immunodeficiency dis-
eases were excluded. Subjects were excluded if they had recently used
other investigational drugs, and they were not allowed to ingest grapefruit
juice, St. John’s wort, or agents that can interact with either KAE609 or
PPQ for at least 7 days prior to dosing and during the study. All patients
provided written informed consent, and the study was approved by the
ethics committee at each participating site.
Study design. This was an open-label, parallel-group, single-dose,
randomized study in healthy volunteers. The dose of KAE609 currently
being evaluated for use in malaria is 75 mg. The highest approved dose of
PPQ used clinically in Eurartesim is 1,280 mg once a day (fasting) for 3
days. Prior to study initiation, SimCYP (Certara) simulations usingmida-
zolam as a surrogate for PPQ (substrate for CYP3A4) suggested that
KAE609 could potentially increase the exposure to PPQbyup to 2-fold (as
a worst-case scenario). Based on the in vitro data, an increase in KAE609
exposure by PPQ of up to 4-fold (worst-case scenario) was predicted
(DDI Predict version 1.7; Aureus Sciences, France). As PPQ has known
exposure-related effects on the QT interval and there was concern regard-
ing potential additional pharmacodynamic (PD) effects on the QT inter-
val, the doses of KAE609 and PPQ were reduced in the arms evaluating
each as the subject of the potential drug-drug interaction (see below). The
long elimination half-life of PPQ (22 days) and the potential for further
prolongation of the half-life with coadministration with KAE609 made a
crossover design nonfeasible, because of the long washout periods that
would be required. Therefore, the parallel-group design was selected for
this study, to address the pharmacokinetic interactions and safety evalu-
ations for the two study drugs singly and in combination.
The study consisted of four treatment arms, which were conducted in
parallel. Arms A through C included one cohort each, whereas arm D
included two cohorts. Approximately 108 eligible subjects were to be ran-
domly assigned to the 5 cohorts in the four dosing arms, in a 24:24:24:
24:12 ratio. Arm A (cohort 1) received a single morning dose of 75 mg
KAE609 plus a single dose of 320 mg PPQ. Arm B (cohort 2) received a
single morning dose of 25mg KAE609 and a single dose of 1,280mg PPQ.
Arm C (cohort 3) received a single morning dose of 25 mg KAE609 only.
In cohort 4 in arm D, subjects received a single morning dose of 320 mg
PPQonly; in cohort 5 in armD, subjects received a singlemorning dose of
1,280 mg PPQ only. Subjects who met the inclusion criteria at screening
were admitted to baseline evaluations at the trial sites (day 1). Eligible
subjects fasted overnight, were dosed on day 1, and thenwere domiciled at
the site from baseline until 24 h postdosing. Subjects then returned to the
site at defined times for an 8-week period (arms A, B, and D) or for an
11-day period (arm C), to undergo safety evaluations and PK sampling.
Study completion evaluations were conducted after the last PK sampling
on day 61 (end of study). The total study duration for subjects in arms A,
B, and Dwas 89 days. ArmC (KAE609monotherapy) had a shorter study
duration (39 days) than arms A, B, and D due to the shorter half-life of
KAE609 (22 to 25 h) compared to PPQ (22 days).
Pharmacokinetic assessments. Sampling for pharmacokinetic analy-
sis in armsA, B, andDoccurred at times 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72,
96, 144, 192, 240, 336, 504, 672, 1,008, and 1,440 h. In arm C (KAE609
alone), pharmacokinetic samples were obtained only to 240 h, using the
aforementioned schedule. KAE609 was analyzed in samples to the 240-h
time point, and piperaquine was analyzed in samples to 1,440 h. Plasma
was isolated within 30 min after blood collection, and tubes were kept
frozen at or below 70°C until analysis. KAE609 and PPQ in plasma
samples were analyzed separately, using validated high-performance
liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)
methods.
For the KAE609 assay, a 10-l aliquot of the reconstituted extract was
analyzed by HPLC-MS/MS in multiple reaction monitoring (MRM)
mode, using electrospray ionization (ESI) as the ionization technique.
KAE609[M6] was used as the internal standard.
For the piperaquine assay, a 50-l aliquot of internal standard (15.0
ng/ml 2H6-labeled piperaquine) and 400 l of methanol were added to a
100-l plasma sample. The mixture was vortex mixed and centrifuged,
the supernatant was dried at 40°C under a stream of nitrogen, and an
aliquot of reconstituted sample was injected into a reverse-phase liquid
chromatography system (Gemini 5-m C18 110A column) with a gradi-
ent mixture for the mobile phase of 0.1% formic acid and 10 mM ammo-
nium acetate in water (pH 4.5) with 0.1% formic acid and 10mM ammo-
nium acetate in 95% methanol (pH 6.5). A mass spectrometer in MRM
mode was used as the detector, with ESI.
The lower limits of quantitation (LLOQs) for KAE609 and PPQ are 1
ng/ml and 0.5 ng/ml, respectively. The linearity ranges for KAE609 and
PPQ are 1 to 5,000 ng/ml and 0.5 to 250 ng/ml, respectively. Accuracy and
precision for both KAE609 and PPQ were within acceptable limits for
study validation. For KAE609, at different concentrations of quality con-
trol samples, the coefficient of variation (CV) (precision) and bias (accu-
racy) were as follows: 2 ng/ml, CV, 10.3%; bias, 4.5%; 5 ng/ml, CV,
4.0%; bias,5.0%; 400 ng/ml, CV, 5.6%; bias,2.3%; 2,000 ng/ml, CV,
4.2%; bias, 4.0%; 4,000 ng/ml, CV, 4.6%; bias, 5.8%. Similarly, for
PPQ, the values were as follows: 1.5 ng/ml, CV, 7%; bias, 0.7%; 15
ng/ml, CV, 4.8%; bias, 1.3%; 75 ng/ml, CV, 3.7%; bias, 1.9%; 200
ng/ml, CV, 4.2%; bias, 4.0%. Concentrations below the limit of quan-
tificationwere treated as zero in summary statistics and for the calculation
of PK parameters. No formal imputation formissing data was performed.
PK parameters of KAE609 and PPQ were determined from the plasma
concentration-time data using the recorded sampling times and noncom-
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partmental methods with WinNonlin Phoenix (version 6.2). The follow-
ing PK parameters were determined: maximum concentration (Cmax),
time to Cmax (Tmax), area under the concentration-time curve (AUC)
from 0 to t (AUC0–t) (t 24 h for KAE609 and t 24, 168, and 672 h for
PPQ), AUC from 0 to the last measurable point (AUClast), AUC from 0 to
infinity (AUCinf), half-life (t1/2), CL/bioavailability (F), and apparent vol-
ume of distribution during the terminal phase (Vz)/F.
Safety assessments. Safety assessments consisted of recording all ad-
verse events (AEs), with their severity and relationship to study drugs,
using the Common Terminology Criteria for Adverse Events (CTCAE)
version 4 grading scale. Regular monitoring of hematological, blood
chemistry, and urinary parameters (plus testing for HIV, HBV, and HCV
at screening) was performed at local laboratories for each center. In addi-
tion, regular assessments of vital signs, full physical examination findings,
and liver safety parameters and monitoring for pregnancies were under-
taken. Standard 12-lead ECGswere performed predosing and 2 h, 4 h, 8 h,
12 h, 24 h, 48 h, 72 h, and 96 h postdosing. These time points were chosen
to capture the period of potentialmaximal exposure risk. ECGevaluations
were performed either as single assessments or in triplicate (baseline
through 24 h), approximately 1 min apart starting approximately 1 min
before the scheduled time. Interpretation of the tracings was performed
by a qualified physician.
Statistical analyses. Pharmacokinetic parameters were summarized
descriptively by treatment group as well as analyzed inferentially. The
logarithmically transformed primary PK parameters (Cmax, AUClast, and
AUCinf) for KAE609 and PPQ were analyzed using a linear fixed-effects
model with treatment as a fixed effect. The analysis was done on the
natural logarithmic scale for PK parameters (Cmax, AUClast, and AUCinf),
and the differences in adjusted means, with 90% confidence intervals
(CIs), were calculated for the comparisons of 75 mg KAE609 plus 320 mg
PPQ versus 320mg PPQ, 1,280mg PPQ plus 25mgKAE609 versus 25mg
KAE609, and 1,280mg PPQplus 25mgKAE609 versus 1,280mg PPQ. All
results for the defined comparisons were back-transformed to the original
scale to present adjusted geometric mean ratios (GMRs) and correspond-
ing 90% confidence intervals. Data for all subjects with at least one PK
parameter were considered in the statistical analysis.
For ECG values, the means of triplicate readings were calculated be-
fore the statistical analysis was performed. These values were obtained by
subtracting themean of triplicate predoseQTcF (orQT interval corrected
by Bazett’s method [QTcB]) values from the mean of triplicate or single-
point postdose QTcF (or QTcB) values for each subject and time point.
The change from baseline for QTcF (or QTcB) for each time point was
analyzed using a linear fixed-effects model with treatment as a fixed effect
and the baseline value (taken as 0 h on day 1) as a covariate. The differ-
ences in adjusted means, with 90% confidence intervals, were calculated
for the comparisons of 75 mg KAE609 plus 320 mg PPQ versus 320 mg
PPQ, 75 mg KAE609 plus 320 mg PPQ versus 1,280 mg PPQ, and 75 mg
KAE609 plus 320 mg PPQ versus 25 mg KAE609; 1,280 mg PPQ plus 25
mg KAE609 was contrasted with 1,280 mg PPQ, with 320 mg PPQ, and
with 25 mg KAE609. Similar analyses were performed separately for the
maximal changes from baseline for QTcF for KAE609 concentrations
alone and in the presence of PPQand for PPQconcentrations alone and in
the presence of KAE609, using a linear fixed-effects model with treatment
as a fixed effect and the concentrations of KAE609 and PPQ at maximal
change as covariates. The differences in adjusted means, with 90% confi-
dence intervals, were calculated for the comparisons of 75 mg KAE609
plus 320 mg PPQ versus 320 mg PPQ, 1,280 mg PPQ plus 25 mg KAE609
versus 1,280mgPPQ, and 1,280mgPPQplus 25mgKAE609 versus 25mg
KAE609. Similar analyses were also performed for the QTcB, PR interval,
and QRS interval.
The study was designed to have 80% power to detect at least a 30%
difference inAUCorCmax, assumingCVs of 32% forKAE609 and 24% for
PPQ, based on a conservative review of prior clinical data, if there were at
least 20 subjects per KAE609 or PPQ arm in the comparisons. To account
for potential dropouts, the target enrollmentwas 25 per arm except for the
arm with 1,280 mg PPQ alone (n 12). The arm with 1,280 mg PPQ was
not for direct PK comparisons but was for additional exposure-response
data and safety data on PPQ.
RESULTS
Subjects. A total of 110 subjects were enrolled and randomized,
with 25 in arm A (cohort 1; 75 mg KAE609 plus 320 mg PPQ), 24
in arm B (cohort 2; 25mg KAE609 plus 1,280mg PPQ), 25 in arm
C (cohort 3; 25 mg KAE609), 24 in cohort 4 in arm D (320 mg
PPQ), and 12 in cohort 5 in armD (1,280 mg PPQ). Overall, 90%
of subjects completed the study. Discontinuation rates were high-
est in the groups that received 1,280 mg PPQ (3/12 subjects
[25%]) and 75 mg KAE609 plus 320 mg PPQ (5/25 subjects
[20%]). For all except one of the subjects who discontinued, the
reason was withdrawal of consent. The remaining subject (in the
group that received 25 mg KAE609) discontinued due to a proto-
col violation; this subject had a pulse rate outside the permissible
range at baseline and discontinued on day 7. All subjects in each
treatment group had evaluable PK and PD data up to the time of
discontinuation and so were included in the PK and PD analysis
sets. Baseline demographic characteristics were similar between
treatment arms. All subjects were male, with a mean age of 25.8
years and a mean weight of 75.7 kg. Most subjects (81.8%) were
Caucasian.
PK parameters for KAE609 in plasma in the presence and
absence of PPQ. KAE609 concentration-time profiles according
to treatment group are shown in Fig. 1 (arithmetic means) and
Fig. 2 (medians). The apparent flattening of the semilogarithmic
curve in Fig. 1 for the group that received 25 mg KAE609 plus
1,280 mg piperaquine was due to a single outlier (subject 1002
00051). This subject had a KAE609 concentration at 192 h of 45.1
ng/ml, with corresponding concentrations for the other subjects
in this treatment group ranging from 0 to 3.14 ng/ml. Semiloga-
rithmic plots of median KAE609 concentrations (which mini-
mized the effects of outliers) did not show flattening of the curve
for the group that received 25 mg KAE609 plus 1,280 mg piper-
aquine (Fig. 2).
All KAE609 PK parameters measured for the group that re-
ceived 25 mg KAE609 plus 1,280 mg PPQ were similar to those
observed for the group that received 25 mg KAE609 (Table 1).
Calculation of the geometric mean ratios (GMRs) for the primary
KAE609 PK parameters for the two treatment groups indicated
FIG 1 Semilogarithmic plots of arithmetic mean KAE609 plasma concentra-
tions according to time and treatment group. Inset, first 24 h after dosing.
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that exposure to KAE609 was not affected by coadministration of
PPQ, i.e., for AUCinf, the GMR was 1.03 (90% CI, 0.87 to 1.22),
and for AUClast, the GMR was 1.02 (90% CI, 0.86 to 1.20). There
was, however, a 17% decrease in the KAE609 Cmax in the presence
of 1,280 mg PPQ (GMR, 0.83 [90% CI, 0.73 to 0.94]).
PK parameters for PPQ in plasma in the presence and ab-
sence of KAE609. Exposure to PPQ was influenced by coadmin-
istration of KAE609, but the effects with increasing KAE609 doses
were inconsistent. Figure 3 presents a semilogarithmic plot of
mean PPQ concentrations over time according to treatment
group.
Coadministration of 25 mg KAE609 with 1,280 mg PPQmod-
estly increased PPQ exposure, whereas coadministration of 75mg
KAE609with 320mgPPQappeared to yield similar PPQ exposure
(Fig. 3 and Table 2). Geometric means for Cmax, AUClast, and
AUCinf were compared for the different cohorts (25 mg KAE609
plus 1,280mg PPQ versus 1,280mg PPQ, and 75mgKAE609 plus
320 mg PPQ versus 320 mg PPQ). This analysis indicated that
coadministration of 75mgKAE609with 320mg PPQ led to a 10%
decrease in AUClast (GMR, 0.90 [90%CI, 0.72 to 1.12]) and a 14%
decrease in AUCinf (GMR, 0.86 [90% CI, 0.70 to 1.07]) for PPQ,
together with a 12% increase inCmax (GMR, 1.12 [90%CI, 0.85 to
1.49]). In contrast, coadministration of 25mg KAE609 with 1,280
mg PPQ was associated with a 28% increase in AUClast (GMR,
1.28 [90% CI, 0.96 to 1.72]) and a 32% increase in AUCinf (GMR,
1.32 [90%CI, 0.98 to 1.78]). A 28% increase in PPQCmax was also
observed in the presence of 25 mg KAE609 (GMR, 1.28 [90% CI,
0.90 to 1.81]). The reasons for the inconsistent and nonsignificant
dose effects of KAE609 on PPQ exposure are unclear.
Safety and tolerability. In this study, 54.5% of subjects expe-
rienced at least one adverse event (AE). None of the AEs was seri-
ous, none was graded 3 or 4, and all resolved by the end of the
study; no patient discontinued due to an AE. The highest overall
rate of AEs was observed in the group that received 1,280mg PPQ.
The most common AEs in all treatment groups were classified as
infections and infestations, nervous system disorders, and gastro-
intestinal disorders; no other system or organ class showed AEs
affecting more than 10% of the total safety set. There were no AEs
affecting the cardiovascular system. Themost commonAE overall
was upper respiratory tract infection, followed by headache in all
groups except the group that received 75mg KAE609 plus 320mg
PPQ (for which oropharyngeal pain was the second most com-
mon AE) (Table 3). In addition to upper respiratory tract infec-
tions, headache, and oropharyngeal pain, other AEs that occurred
inmore than one subject were diarrhea, gastritis, abdominal pain,
and dry skin. The treatment groups showed some differences in
the rates of AEs, but there were no obvious patterns and the dif-
ferences are difficult to interpret, given the small numbers of AEs.
KAE609 does not affect QTc. PPQ is known to increase the
FIG 2 Semilogarithmic plots of median KAE609 concentrations according to
time and treatment group (full profile).Œ, 75mgKAE609 plus 320mgPPQ; #,
25 mg KAE609 plus 1,280 mg PPQ;, 25 mg KAE609.
TABLE 1 Plasma PK parameters for KAE609 in the presence and absence of piperaquine
Parameter
Value for treatment group receiving:
75 mg KAE609 320 mg PPQ
(n 25)a
25 mg KAE609 1,280 mg PPQ
(n 24) 25 mg KAE609 (n 25)b
Cmax (mean	 SD [%CV]) (ng/ml) 760	 176 (23.2) 226	 60.0 (26.6) 269	 57.5 (21.3)
Tmax (median [range]) (h) 3.00 (1.00–46.5) 3.00 (2.00–6.00) 3.00 (1.00–12.0)
AUC0–24 (mean	 SD [%CV]) (g · h/ml) 9.35	 1.90 (20.4) 2.77	 0.80 (28.7) 2.93	 0.70 (23.9)
AUClast (mean	 SD [%CV]) (g · h/ml) 18.6	 5.53 (29.8) 5.87	 3.97 (67.6) 5.35	 1.44 (26.8)
AUCinf (mean	 SD [%CV]) (g · h/ml) 18.6	 5.55 (29.8) 6.10	 4.54 (74.5) 5.42	 1.45 (26.7)
t1/2 (mean	 SD [%CV]) (h) 24.4	 6.82 (28.0) 26.4	 13.0 (49.1) 25.2	 9.12 (36.2)
Vz/F (mean	 SD [%CV]) (liters) 149	 46.4 (31.2) 172	 56.9 (33.1) 170	 49.3 (28.9)
CL/F (mean	 SD [%CV]) (liters/h) 4.34	 1.16 (26.6) 5.01	 1.76 (35.1) 4.98	 1.53 (30.7)
a n 23 for AUClast, AUCinf, t1/2, and Vz/F.
b n 24 for AUClast, AUCinf, t1/2, and Vz/F.
FIG 3 Semilogarithmic plots of arithmetic mean piperaquine plasma concen-
trations according to time and treatment group. Œ, 75 mg KAE609 plus 320
mg PPQ; #, 25 mg KAE609 plus 1,280 mg PPQ;o, 320 mg PPQ;, 1,280 mg
PPQ. Inset, first 24 h after dosing.
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QTc (9, 10). Therefore, ECG evaluations were performed for all
cohorts using QTcF values in the primary analysis. No mean in-
crease in QTcF was seen except for the two treatment groups that
received 1,280 mg PPQ (Fig. 4). There appeared to be little differ-
ence in ECG results between the group that received 1,280 mg
PPQ alone and the group that received 25 mg KAE609 plus 1,280
mg PPQ or between the group that received 320 mg PPQ alone
and the group that received 320mg PPQ plus 75mg KAE609. The
group that received 25 mg KAE609 did not show an increase in
QTcF at any time point.
A statistical analysis of treatment comparisons for maximal
changes in QTcF from baseline for the first 24 h postdose is pre-
sented in Table 4; it uses a linear fixed-effects model with treat-
ment as a fixed effect and the PPQ concentration at maximal
change as a covariate. There were no statistically significant differ-
ences in the comparisons of 25 mg KAE609 plus 1,280 mg PPQ
versus 1,280mg PPQ and 75mg KAE609 plus 320mg PPQ versus
320 mg PPQ. This was also the case when the analysis was per-
formed with treatment as a fixed effect and PPQ Cmax as a covari-
ate (data not shown). This further indicates that KAE609 does not
affect the QTcF increases observed with PPQ. A statistical analysis
of the comparison of 25mg KAE609 plus 1,280mg PPQ versus 25
mg KAE609 with treatment as a fixed effect and KAE609 concen-
tration as a covariate (Table 4) showed a significantly greatermax-
imal change from baseline for 25 mg KAE609 plus 1,280 mg PPQ
than for 25 mg KAE609 (least-squares means of 11.2 and 3.70 ms,
respectively, with a least-squares estimate of the difference of 7.47
ms [90% CI, 3.55 to 11.4 ms]; P  0.0025) (Table 4). Similar
results were obtained when treatment was used as a fixed effect
and KAE609 Cmax as a covariate (data not shown). None of the
subjects in any of the other treatment groups demonstrated an
increase in QTcF of 30 ms or a newly occurring QTcF value of
450ms. A similar analysis ofQTcB values was in agreementwith
the QTcF results. These data confirmed that PPQ is significantly
associated with QTc increases, but they showed that KAE609
alone does not affect QTc and the drug does not potentiate the
cardiac effects of PPQ when given in combination.
Data were pooled across treatment groups to investigate the
exposure effects of KAE609 or PPQ alone or in combination on
the change in QTcF from baseline. There was no apparent rela-
tionship between KAE609 concentrations and changes in QTcF
from baseline; this was the case for KAE609 alone and in the pres-
TABLE 2 PK parameters for piperaquine in the presence and absence of KAE609
Parameter
Value for treatment group receiving:
75 mg KAE609 320 mg
PPQ (n 25)a
1,280 mg PPQ 25 mg
KAE609 (n 24)b 320 mg PPQ (n 24)c 1,280 mg PPQ (n 12)d
Cmax (mean	 SD [%CV]) (ng/ml) 24.2	 16.8 (69.4) 299	 191 (63.7) 20.4	 8.40 (41.2) 219	 124 (56.6)
Tmax (median [range]) (h) 3.00 (1.00–46.5) 3.00 (2.00–6.00) 3.00 (1.00–12.0) 3.00 (1.00–4.00)
AUC0–24 (mean	 SD [%CV]) (g · h/ml) 0.27	 0.14 (53.0) 2.30	 1.00 (43.2) 0.243	 0.09 (38.9) 1.84	 0.84 (45.8)
AUC0–168 (mean	 SD [%CV]) (g · h/ml) 0.84	 0.40 (47.4) 5.15	 1.89 (36.8) 0.850	 0.33 (38.2) 4.15	 1.47 (35.4)
AUC0–672 (mean	 SD [%CV]) (g · h/ml) 1.72	 0.92 (53.4) 8.49	 2.84 (33.5) 1.74	 0.68 (39.4) 6.70	 2.13 (31.8)
AUClast (mean	 SD [%CV]) (g · h/ml) 2.07	 1.28 (61.6) 10.8	 3.53 (32.7) 2.16	 0.98 (45.4) 8.36	 2.64 (31.5)
AUCinf (mean	 SD [%CV]) (g · h/ml) 2.60	 1.49 (57.2) 12.0	 3.70 (30.9) 2.82	 1.13 (40.1) 8.99	 2.86 (31.8)
t1/2 (mean	 SD [%CV]) (h) 510	 339 (66.6) 485	 113 (23.3) 551	 284 (51.5) 536	 172 (32.1)
Vz/F (mean	 SD [%CV]) (liters) 99,300	 49,500 (49.9) 83,400	 35,000 (41.9) 96,700	 44,500 (46.0) 125,000	 71,700 (57.5)
CL/F (mean	 SD [%CV]) (liters/h) 155	 80.9 (52.4) 120	 50.0 (41.7) 131	 59.9 (45.6) 155	 46.1 (29.8)
a n 22 for AUClast, n 21 for t1/2 and Vz/F, and n 19 for AUCinf.
b n 21 for AUClast, AUCinf, t1/2, and Vz/F.
c n 22 for AUCinf, t1/2, and Vz/F.
d n 9 for AUClast and n 7 for AUCinf, t1/2, and Vz/F.
TABLE 3 Incidences of AEs according to preferred terms
Preferred terma
No. (%) of subjects
75 mg KAE609 320 mg
PPQ (n 25)
25 mg KAE609 1,280 mg
PPQ (n 24)
25 mg KAE609
(n 25)
320 mg PPQ
(n 24)
1,280 mg PPQ
(n 12)
Total
(n 110)
At least one AE 12 (48.0) 15 (62.5) 10 (40.0) 14 (58.3) 10 (83.3) 61 (55.5)
Upper respiratory tract infection 4 (16.0) 6 (25.0) 4 (16.0) 8 (33.3) 8 (66.7) 30 (27.3)
Headache 0 (0.0) 2 (8.3) 4 (16.0) 4 (16.7) 2 (16.7) 12 (10.9)
Diarrhea 0 (0.0) 2 (8.3) 2 (8.0) 1 (4.2) 0 (0.0) 5 (4.5)
Oropharyngeal pain 3 (12.0) 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 4 (3.6)
Photosensitivity reaction/sunburnb 1 (4.0) 1 (4.2) 1 (4.0) 0 (0.0) 0 (0.0) 3 (2.7)
Gastritis 0 (0.0) 2 (8.3) 0 (0.0) 1 (4.2) 0 (0.0) 3 (2.7)
Contusion 0 (0.0) 1 (4.2) 1 (4.0) 1 (4.2) 0 (0.0) 3 (2.7)
Abdominal pain 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.3) 0 (0.0) 2 (1.8)
Myalgia 1 (4.0) 0 (0.0) 1 (4.0) 0 (0.0) 0 (0.0) 2 (1.8)
Lethargy 0 (0.0) 0 (0.0) 1 (4.0) 0 (0.0) 1 (8.3) 2 (1.8)
Dry skin 0 (0.0) 2 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.8)
a AEs are presented in descending order of total frequency.
b These two preferred terms were combined due to their clinical similarity on the basis of reported terms.
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ence of PPQ (Fig. 5). The R2 for KAE609 plus PPQ was 0.0273
(P  0.01), and that for KAE609 alone was 0.0003 (P  0.8365).
For PPQ, there was an indication of a concentration-dependent
effect on changes inQTcF frombaseline, but this responsewas not
affected by the presence of KAE609 (Fig. 6). The R2 for KAE609
plus PPQ was 0.0709 (P 
 0.0001), and that for PPQ alone was
0.0693 (P 0.0004).
DISCUSSION
The current study assessed the safety, tolerability, and drug-drug
interaction potential of KAE609 and PPQ administered alone or
in combination to healthy subjects. Both drugs, when adminis-
tered alone or coadministered, appeared to bewell tolerated by the
study volunteers. There were no serious adverse events, severe
adverse events, or adverse events that led to discontinuation from
the study. The most commonly reported AEs were upper respira-
tory tract infections, headache, diarrhea, and oropharyngeal pain.
There were no consistent differences between the treatment
groups, and there were no obvious increases in the rates of specific
AEs when PPQ andKAE609were coadministered, comparedwith
administration of PPQ alone.
The ability of KAE609 and PPQ to affect cardiac conduction
when given alone or in combinationwas also tested. PPQ is known
to be associated with QTc prolongation in human studies (9, 10)
and, although no significant changes in ECG parameters were ob-
served in clinical studies of KAE609 (7), preclinical evaluations
indicated this as a potential risk (unpublished Novartis data). The
data from this study indicated that the mean maximal changes in
QTcF and QTcB from baseline following a single PPQ dose were
consistent with the known effects of the drug. A difference in
QTcF of 7.47ms (90%CI, 3.55 to 11.4ms)was found for PPQplus
KAE609 versus KAE609 alone. The labeling for Eurartesim indi-
cates a much greater QTcF increase after 3 days of dosing, which
achieves approximately 3 times the PPQ exposure of a single dose.
The magnitude of the change observed in this study and the Eu-
rartesim labeling would be consistent with a positive thorough
QTc study according to ICH E14 guidelines. In contrast, a single
dose of KAE609 administered alone did not show an effect on the
QTc, and QTcF and QTcB changes showed no correlation with
KAE609 concentrations. Furthermore, coadministration of
KAE609 did not potentiate the effects of PPQ on QTc. No cardio-
vascular AEs were reported for any subject.
Preclinical data also suggested a potential risk for phototoxicity
from KAE609 exposure. Three light-related AEs were reported.
All were of mild intensity and they did not exhibit a pattern sug-
gesting a dose-response relationship for either KAE609 or PPQ.
Two of these AEs were suspected by the investigators to be related
to a study drug (one on day 2 in the group that received 75 mg
KAE609 plus 320 mg PPQ, and one on day 3 in the group that
FIG 4 Arithmetic means (and standard deviations) of changes in QTcF from
baseline according to time and treatment group. At predosing and 2, 4, 8, 12,
and 24 h postdosing, triplicate ECG assessments weremade. The average of the
triplicate assessments was calculated, and the change from baseline is shown.
Baseline was taken at 0 h on day 1.Œ, 75 mg KAE609 plus 320 mg PPQ; #, 25
mg KAE609 plus 1,280 mg PPQ;o, 320 mg PPQ;, 1,280 mg PPQ;, 25 mg
KAE609.
TABLE 4 Statistical analysis of comparisons for mean maximal changes in QTcF from baseline
Treatment comparison
LS mean maximal change from baseline (ms)a
LS estimate of difference
(90% CI) (ms) P
75 mg KAE609
320 mg PPQ
25 mg KAE609
1,280 mg PPQ
320 mg
PPQ
1,280 mg
PPQ
1,280 mg PPQ
25 mg KAE609
25 mg
KAE609
75 mg KAE609 320 mg
PPQ vs 320 mg PPQ
5.04 5.90 0.86 (4.41 to 2.68) 0.6864
25 mg KAE609 1,280 mg
PPQ vs 1,280 mg PPQ
9.50 7.12 2.37 (2.08 to 6.82) 0.3775
25 mg KAE609 1,280 mg
PPQ vs 25 mg KAE609
11.20 3.70 7.47 (3.55–11.4) 0.0025
a At predosing and 2, 4, 8, 12, and 24 h postdosing, triplicate ECG assessments were available. Averages of triplicate assessments were calculated, and the values for baseline and
changes from baseline were derived accordingly. The repeated measurements were not taken into account for the calculation of statistics. The maximal changes from baseline for
ECG intervals of less than 24 h were analyzed using a linear fixed-effects model with treatment as a fixed effect and KAE609 and PPQ concentrations at maximal changes as
covariates. LS, least-squares.
FIG 5 KAE609 concentration effects on changes in QTcF from baseline for
KAE609 alone and in the presence of piperaquine., KAE609 plus PPQ;, 25
mg KAE609. Solid line, regression for KAE609 plus PPQ; dotted line, regres-
sion for 25mgKAE609.R2 0.0273 for KAE609 plus PPQ;R2 0.0003 for 25
mg KAE609.
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received 25 mg KAE609). The investigators’ interpretation was
that these subjects had increased vision sensitivity to light. The
subject in the group that received 25 mg KAE609 reported a long
history of intermittent similar symptoms. The third case involved
sunburn (on day 27) in a subject in the group that received 25 mg
KAE609 plus 1,280 mg PPQ. This was not suspected by the inves-
tigators to be related to a study drug, as the subject had experi-
enced sunburn after falling asleep on a beach.
This study evaluated the effects of combination treatment on
exposure to each drug. Both KAE609 and PPQ are substrates for
CYP3A4. PPQ is also a CYP3A inhibitor, based on the approved
label for Eurartesim (9), while in vitro studies (unpublished No-
vartis data) have shown that KAE609 does not induce CYP3A but
has a low potential to inhibit the enzyme. Prior to study initiation,
SimCYP simulations usingmidazolam (awell-characterized high-
clearance CYP3A4 substrate) as a surrogate for PPQ (CYP3A4
substrate) suggested that KAE609 could potentially increase the
exposure to PPQ by up to 2-fold (as a worst-case scenario). Based
on the in vitro interaction data and limited clinical data, an in-
crease in KAE609 exposure of up to 4-fold (worst-case scenario)
with PPQwas predicted (DDIPredict). The results from this study
indicated a low degree of interaction, as coadministration of PPQ
was found to have no overall effect on exposure to KAE609 in
healthy subjects, although theKAE609Cmaxwas decreased by 17%
in the group that received 75 mg KAE609 plus 320 mg PPQ, com-
pared with the group that received 320 mg PPQ. Coadministra-
tion of KAE609 had inconsistent and nonsignificant effects on
exposure to PPQ. The reasons for this observation are unknown,
but both comparisons had high variability, as shown by the wide
confidence intervals. The study was designed to have at least 80%
power to detect differences in AUC or Cmax in geometric mean
ratio comparisons for KAE609 and PPQ if there were at least 20
subjects per arm. To account for potential dropouts, the study
actually enrolled more than 20 subjects per arm; therefore, the
power to detect differences was greater. It is unlikely that these
small observed effects following coadministration would be clin-
ically relevant, given the long exposure time for PPQ. Other
KAE609 and PPQ pharmacokinetic parameters were not affected
by coadministration of the partner drug.
On the basis of this study, KAE609 and PPQ could be admin-
istered in combination without the need for dose adjustment for
either compound. PPQ coadministration had no effect on expo-
sure to KAE609, and the effects of KAE609 on PPQ exposure were
small and inconsistent. As the effects of inhibitionwould be found
with a single dose and no time-dependent effects for either drug
have been observed, it is probable that these results can be extrap-
olated to multiple-dose use. KAE609 does not appear to have a
significant effect on cardiac conduction and does not potentiate
the known effects of PPQ.
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